Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Vaccines )
ClinicalTrials.gov Identifier:
NCT01162122
First received: July 13, 2010
Last updated: June 16, 2014
Last verified: June 2014
  Purpose

The present phase III study aims to evaluate the safety and immunogenicity of MF59-adjuvanted subunit seasonal influenza vaccine and to evaluate the consistency in the manufacturing process of three consecutive lots of MF59-adjuvanted subunit seasonal influenza vaccine with respect to immunogenicity in subjects aged 65 years and older. The active comparator non-adjuvanted seasonal influenza vaccine is approved for use in this age group in the United States and will be used to provide a comparative assessment for immunogenicity and safety.


Condition Intervention Phase
Influenza
Biological: MF59 adjuvanted trivalent subunit influenza vaccine (aTIV)
Biological: Non-adjuvanted trivalent subunit influenza vaccine (TIV)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase III, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety and Immunogenicity and the Consistency of Three Consecutive Lots of a MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects Aged 65 Years and Older

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Geometric Mean Titers in Subjects After Receiving One Dose of Lot 1 or Lot 2 or Lot 3 of aTIV [ Time Frame: Day 22 post vaccination ] [ Designated as safety issue: No ]
    Immunologic equivalence of 3 consecutive production lots of aTIV (Lot 1, Lot 2 and Lot 3), was assessed in terms of Hemagglutination Inhibition (HI) Geometric Mean Titers (GMTs) in subjects, at three weeks after vaccination, against each vaccine strain.

  • Comparison of aTIV Versus TIV in Terms of Geometric Mean Titers (GMTs) Against Homologous Strains - PPS [ Time Frame: Day 22 post vaccination ] [ Designated as safety issue: No ]
    The non-inferiority of HI antibody responses of aTIV compared to TIV assessed in terms of post vaccination GMTs at three weeks after vaccination against the three homologous vaccine strains.

  • Comparison of aTIV Versus TIV in Terms of Percentage of Subjects Achieving Seroconversion Against Homologous Strains-PPS [ Time Frame: Day 22 post vaccination ] [ Designated as safety issue: No ]

    The non-inferiority of HI antibody responses of aTIV compared to TIV assessed in terms of percentage of subjects achieving seroconversion at three weeks after vaccination against the three homologous vaccine strains.

    Seroconversion defined as prevaccination HI titer <10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.


  • Comparison of aTIV Versus TIV in Terms of GMTs Against Homologous Strains-Full Analysis Set (FAS) [ Time Frame: Day 22 post vaccination ] [ Designated as safety issue: No ]
    The superiority of HI antibody responses of aTIV compared to TIV assessed in terms of post vaccination GMTs at three weeks after vaccination against the three homologous vaccine strains.

  • Comparison of aTIV Versus TIV in Terms of Percentage of Subjects Achieving Seroconversion Against Homologous Strains-FAS [ Time Frame: Day 22 post vaccination ] [ Designated as safety issue: No ]

    The superiority of HI antibody responses of aTIV compared to TIV assessed in terms of percentage of subjects achieving seroconversion at three weeks after vaccination against the three homologous vaccine strains.

    Seroconversion defined as prevaccination HI titer <10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.


  • Percentage of Subjects With HI Titers ≥40 Against Homologous Strains [ Time Frame: Day 22 post vaccination ] [ Designated as safety issue: No ]
    The percentage of subjects demonstrating HI titers ≥40, in overall group and in subjects with pre-defined co-morbidities (high risk group), against homologous strains, three weeks after vaccination with aTIV or TIV.

  • Percentage of Subjects Achieving Seroconversion in HI Titers, Against Homologous Strains [ Time Frame: Day 22 post vaccination ] [ Designated as safety issue: No ]

    The percentage of subjects achieving seroconversion in HI titers from baseline, in overall group and in subjects with pre-defined co-morbidities (high risk group), against homologous strains, three weeks after vaccination with aTIV or TIV.

    Seroconversion is defined as prevaccination HI titer <10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.


  • Geometric Mean Ratio (GMR) of Post- Versus Pre-vaccination HI Titers Against Homologous Strains [ Time Frame: Day 22 post vaccination ] [ Designated as safety issue: No ]
    The GMR of post-vaccination versus pre-vaccination HI titers (day 22/day 1) in overall group and in subjects with pre-defined co-morbidities (high risk group), against homologous strains, three weeks after vaccination with aTIV or TIV.

  • Percentage of Subjects With HI Titers ≥40 Against Heterologous Strains [ Time Frame: Day 22 post vaccination ] [ Designated as safety issue: No ]
    The percentage of subjects demonstrating HI titers ≥40, in overall group and in subjects with pre-defined co-morbidities (high risk group), against heterologous strains, three weeks after vaccination with aTIV or TIV.

  • Geometric Mean Ratio (GMR) of Post- Versus Pre-vaccination HI Titers, Against Heterologous Strains [ Time Frame: Day 22 post vaccination ] [ Designated as safety issue: No ]
    The GMR of post-vaccination versus pre-vaccination HI titers (day 22/day 1) in overall group and in subjects with pre-defined co-morbidities (high risk group), against heterologous strains, three weeks after vaccination with aTIV or TIV.

  • Percentage of Subjects Achieving Seroconversion in HI Titers, Against Heterologous Strains [ Time Frame: Day 22 post vaccination ] [ Designated as safety issue: No ]

    The percentage of subjects achieving seroconversion in HI titers from baseline, in overall group and in subjects with pre-defined co-morbidities (high risk group), against heterologous strains, three weeks after vaccination with aTIV or TIV.

    Seroconversion is defined as prevaccination HI titer <10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.



Secondary Outcome Measures:
  • Comparison of aTIV Versus TIV in High Risk Group in Terms of GMTs Against Homologous Strains-PPS [ Time Frame: Day 22 post vaccination ] [ Designated as safety issue: No ]
    The non-inferiority of HI antibody responses of ATIV compared to TIV, in subjects with pre-defined co-morbidities (high risk subjects), was assessed in terms of post vaccination GMTs at three weeks after vaccination against the three homologous vaccine strains.

  • Comparison of HI Antibody Responses of aTIV Versus TIV, in High Risk Group in Terms of Percentage of Subjects Achieving Seroconversion Against Homologous Strains-PPS [ Time Frame: Day 22 post vaccination ] [ Designated as safety issue: No ]

    The non-inferiority of HI antibody responses of ATIV compared to TIV, in subjects with pre-defined co-morbidities (high risk group), assessed in terms of percentage of subjects achieving seroconversion at three weeks after vaccination against the homologous vaccine strains.

    Seroconversion is defined as prevaccination HI titer <10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.


  • Comparison of aTIV Versus TIV in High Risk Group in Terms of GMTs Against Homologous Strains-FAS [ Time Frame: Day 22 post vaccination ] [ Designated as safety issue: No ]
    The superiority of HI antibody responses of aTIV compared to TIV, in subjects with predefined co-morbidities (high risk group) assessed in terms of post vaccination GMTs at three weeks after vaccination against the three homologous vaccine strains.

  • Comparison of HI Antibody Responses of aTIV Versus TIV, in High Risk Group in Terms of Percentage of Subjects Achieving Seroconversion Against Homologous Strains-FAS [ Time Frame: Day 22 postvaccination ] [ Designated as safety issue: No ]

    The superiority of HI antibody responses of aTIV compared to TIV, in subjects with pre-defined co-morbidities (high risk group), assessed in terms of percentage of subjects achieving seroconversion at three weeks after vaccination against the homologous vaccine strains.

    Seroconversion is defined as prevaccination HI titer <10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.


  • Comparison of aTIV Versus TIV in Terms of GMTs Against Heterologous Strains-PPS [ Time Frame: Day 22 post vaccination ] [ Designated as safety issue: No ]
    The non-inferiority of HI antibody responses of aTIV compared to TIV against the heterologous vaccine strains, in overall group and in subjects with pre-defined co-morbidities (high risk subjects), was assessed in terms of post vaccination GMTs at three weeks after vaccination .

  • Comparison of aTIV Versus TIV in Terms of GMTs Against Heterologous Strains-FAS [ Time Frame: Day 22 post vaccination ] [ Designated as safety issue: No ]
    The superiority of HI antibody responses of aTIV compared to TIV against the heterologous vaccine strains, in overall group and in subjects with pre-defined co-morbidities (high risk subjects), was assessed in terms of post vaccination GMTs at three weeks after vaccination.

  • Comparison of HI Antibody Responses of aTIV Versus TIV, in Terms of Percentage of Subjects Achieving Seroconversion Against Heterologous Strains-PPS [ Time Frame: Day 22 postvaccination ] [ Designated as safety issue: No ]

    The non-inferiority of HI antibody responses of aTIV compared to TIV against the heterologous strains, in overall group and in subjects with pre-defined co-morbidities (high risk group), assessed in terms of percentage of subjects achieving seroconversion at three weeks after vaccination.

    Seroconversion is defined as prevaccination HI titer <10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.


  • Comparison of aTIV Versus TIV in Terms of Percentage of Subjects Achieving Seroconversion Against Heterologous Strains-FAS [ Time Frame: Day 22 post vaccination ] [ Designated as safety issue: No ]

    The superiority of HI antibody responses of aTIV compared to TIV against the heterologous vaccine strains, in overall group and in subjects with pre-defined co-morbidities (high risk subjects), was assessed in terms of percentage of subjects achieving seroconversion, at three weeks after vaccination.

    Seroconversion is defined as prevaccination HI titer <10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.


  • Persistence of GMTs Against Homologous and Heterologous Strains [ Time Frame: Day 181, Day 366 post vaccination ] [ Designated as safety issue: No ]
    The GMTs against homologous and heterologous strains, persisting in subjects at six months (day 181) and one year (day 366) after vaccination with either aTIV or TIV.

  • Percentage of Subjects With Seroconversion Upto One Year After Vaccination, Against Homologous and Heterologous Strains [ Time Frame: Day 181, Day 366 post vaccination ] [ Designated as safety issue: No ]

    The percentage of subjects demonstrating seroconversion in HI titers against homologous and heterologous strains, at six months (day 181) and one year (day 366) after vaccination with either aTIV or TIV.

    Seroconversion is defined as prevaccination HI titer <10 and postvaccination HI titer ≥40 or at least a 4-fold increase in HI titers from prevaccination HI titer ≥10.


  • Number of Subjects Reporting Influenza Like Illness (ILI) Across Vaccine Groups [ Time Frame: Day 22 through Day 366 post vaccination ] [ Designated as safety issue: No ]
    The number of subjects reporting ILI from three weeks after vaccination to up to one year in aTIV group compared to TIV group, by country.

  • Number of High Risk Subjects With Exacerbation of Preexisting Chronic Disease, Across Vaccine Groups [ Time Frame: Day 1 through Day 366 post vaccination ] [ Designated as safety issue: No ]
    The number of high risk subjects reporting exacerbation of preexisting chronic conditions (i.e.congestive heart failure, Chronic Obstructive Pulmonary disease (COPD), asthma, hepatic disease, renal insufficiency, and neurological/neuromuscular or metabolic disorders including diabetes mellitus) in aTIV group compared to TIV group.

  • Number of Subjects Reporting Healthcare Utilization Across Vaccine Groups [ Time Frame: Day 1 through Day 366 post vaccination ] [ Designated as safety issue: No ]
    The number of subjects with emergency room visits, unscheduled physician visits, and hospitalizations due to community acquired influenza or pneumonia, cardiopulmonary disease, cardiac disease, respiratory or pulmonary disease,in aTIV group compared to TIV group.

  • All Cause Mortality Rate, Across Vaccine Groups [ Time Frame: Day 1 through Day 366 post vaccination ] [ Designated as safety issue: No ]
    The all-cause mortality rate (excluding injury)reported in aTIV group compared to TIV group, by country.

  • Number of Subjects Reporting Solicited Adverse Events Following Vaccination [ Time Frame: Day 1 through Day 7 post vaccination ] [ Designated as safety issue: Yes ]
    The number of subjects reporting solicited local and systemic adverse events and other adverse events in aTIV group compared to TIV group.


Enrollment: 7109
Study Start Date: August 2010
Study Completion Date: November 2011
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: aTIV
Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).
Biological: MF59 adjuvanted trivalent subunit influenza vaccine (aTIV)
one dose 0.5 mL administered IM in the deltoid muscle of (preferably) the non-dominant arm
Other Name: Fluad
Experimental: Licensed TIV
Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).
Biological: Non-adjuvanted trivalent subunit influenza vaccine (TIV)
one 0.5 mL dose administered IM in the deltoid muscle of (preferably) the non-dominant arm
Other Name: Agriflu

  Eligibility

Ages Eligible for Study:   65 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Males and females subjects aged ≥65 years at day of vaccination who are willing and able to comply to study procedures.

Exclusion Criteria:

  1. Individuals with behavioral or cognitive impairment or a psychiatric condition or with a history of any illness that,in the opinion of the investigator, would have interfered with the subject's ability to participate in the study.
  2. Individuals who were not able to comprehend and/or follow all required study procedures for the whole period of the study.
  3. Known or suspected impairment/alteration of immune function.
  4. Individuals with a known bleeding diathesis.
  5. History of Guillain-Barré syndrome.
  6. Individuals with history of allergy to vaccine components and/or a history of any anaphylaxis, serious vaccine reactions or hypersensitivity to influenza viral proteins, egg proteins (including ovalbumin), polymyxin, neomycin, betapropiolactone, thimerosal/ sodium ethylmercurothiosalicylate/ mercury and nonylphenolethoxylate/ nonoxynol-9 (spermicide).
  7. Receipt of another investigational agent within 30 days prior to enrollment in the study or before completion of the safety follow-up period in another study.
  8. Individuals who had received any other vaccines within 2 weeks for inactivated vaccines or 4 weeks for live vaccines prior to enrollment in this study or who had planned to receive any vaccine within 3 weeks from the study vaccine.
  9. Individuals who had received vaccination against seasonal influenza in the previous 6 months.
  10. Individuals with oral temperature ≥38.0°C (≥100.4°F) on day of study vaccination.
  11. Individuals with history of substance or alcohol abuse within the past 2 years.
  12. Individuals providing consent who did not consent to the retention of their serum samples after study completion.
  13. Elective surgery or hospitalization planned to occur during the treatment phase or during the follow-up phase that, according to the opinion of the investigator, might have poses additional risk to the subject.
  14. Subjects from whom blood could not be drawn at visit 1.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01162122

  Hide Study Locations
Locations
United States, Arizona
301, Tatum Highlands Medical Associates PLLC, 26224 N Tatum Blvd 15A
Phoenix, Arizona, United States, 85253
United States, Florida
318 Avail Clinical Research, 860 Peachwood Drive
Deland, Florida, United States, 32720
306 Westside Center for Clinical Research, 810 Lane Avenue South
Jacksonville, Florida, United States, 32205
328 Miami Research Associates, 6141 Sunset Drive
Miami, Florida, United States, 33143
United States, Kansas
320 Johnson County Clin-Trials, 15602 College Blvd
Lenexa, Kansas, United States, 66219
316 Heartland Research Associates LLC - Axtell Clinic - PA, 700 Medical Center Dr
Newton, Kansas, United States, 67114
322 Heartland Research Associates Wichita, 1709 S. Rock Road
Wichita, Kansas, United States, 67207
310 Heartland Research Associates LLC, 3730 N Ridge Road Suite 600
Wichita, Kansas, United States, 67205
United States, Missouri
314 Saint Louis Univ Med Div of Infectious Diseases Immunology, 1100 S Grand Blvd DRC- Rm 827
Saint Louis, Missouri, United States, 63104
330 Mercy Health Research, 12680 Olive Blvd Suite 200
Saint Louis, Missouri, United States, 63141
United States, Nevada
313 Clinical Research Center of Nevada, 7425 W Azure Suite 150
Las Vegas, Nevada, United States, 89130
United States, New York
311 Regional Clinical Research INC, 415 Hooper Road
Endwell, New York, United States, 13760
United States, North Carolina
326 Triangle Medical Research, 5816 Creedmoor Rd. Suite 104
Raleigh, North Carolina, United States, 27612
332 Piedmont Medical Research, 1901 S. Hawthorne Rd. Suite 306
Winston-Salem, North Carolina, United States, 27103
United States, Ohio
303 Prestige Clinical Research, 333 Conover Drive
Franklin, Ohio, United States, 45005
United States, Rhode Island
325 Omega Medical Research, 400 Bald Hill Road
Warwick, Rhode Island, United States, 02886
United States, South Carolina
312 Spartanburg Regional Medical Center, 485 Simuel Road
Spartanburg, South Carolina, United States, 29303
United States, Utah
321 Jordan River Family Medicine, 1868 West 9800 South Ste 100
Jordan, Utah, United States
317 J. Lewis Research Inc., 2295 Foothill Drive
Salt Lake City, Utah, United States, 84109
305 Foothill Family Clinic South, 6360 South 3000 East
Salt Lake City, Utah, United States, 84121
United States, Virginia
323 PI Coor Clinical Research LCC, 10721 Main St Suite 1500
Fairfax, Virginia, United States, 22030
Colombia
209, Centro de Investigacion CAFAM
Avenida Carrera 68, Bogota, Colombia
213, Centro de Atencion e Investigacion Medica CAIMED
Carrera 42A, Bogota, Colombia, 1750
206, Centro de Atencion e Investigacion Medica CAIMED
Carrera 42A, Bogota, Colombia, 1750
207, Centro de Investigacion Cafesalud Medicina Prepagada
Cra 14 No Piso Sexto, Bogota, Colombia
Panama
203, Health Research International HRI
Clayton ciudad del Saber Edificio 118, Panama
205, Medical and Research Center Calle 53 Urbanizacion Marbella
Consultorios Royal Center 108, Panama
Philippines
103, De La Salle Health Sciences Institute
DBB B Dasmarinas, Cavite, Philippines, 4114
102, De La Salle Health Sciences Institute
Dbbb Dasmarinas, Cavite, Philippines, 4114
105, Manila Doctors Hospital, 667 United Nations Avenue
Ermita, Manila, Philippines, 1000
106, Our Lady of Lourdes Hospital, 46 P. Sanchez Street Sta.
Mesa, Manila, Philippines, 1016
104 Jose Reyes Memorial Medical Center
Rizal Avenue Avenida Cruz, Manila, Philippines, 1003
107 Philippine General Hospital
Taft Avenue, Manila, Philippines, 1000
101, Asian Hospital and Medical Center 2205 Civic Drive Filinvest
Corporate City Alabang, Muntinlupa, Philippines, 1781
109, Research Institute for Tropical Medicine Department of Health Compound FILINVEST
Corporate City Alabang, Muntinlupa, Philippines
108, City Health Office 1 Rosa City
City Health Office 1, Rosa City, Philippines, 4026
110, San Juan de Dios Hospital, 2772 Roxas Blvd
Pasay City, Philippines, 1300
111, St Lukes Medical Center, 279 E Rodriguez Sr Boulevard
Quezon City, Philippines, 1102
Sponsors and Collaborators
Novartis Vaccines
Investigators
Study Chair: Novartis Vaccines Novartis Vaccines
  More Information

No publications provided

Responsible Party: Novartis ( Novartis Vaccines )
ClinicalTrials.gov Identifier: NCT01162122     History of Changes
Other Study ID Numbers: V70_27
Study First Received: July 13, 2010
Results First Received: January 28, 2014
Last Updated: June 16, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Novartis:
Elderly
Influenza
Immunogenicity
Safety
Adjuvant
Adjuvanted
Adjuvants
Vaccines

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on August 28, 2014